GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Disc Medicine Inc (NAS:IRON) » Definitions » COGS-to-Revenue

Disc Medicine (Disc Medicine) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Disc Medicine COGS-to-Revenue?

Disc Medicine's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

Disc Medicine's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Disc Medicine's Gross Margin % for the three months ended in Dec. 2023 was N/A%.


Disc Medicine COGS-to-Revenue Historical Data

The historical data trend for Disc Medicine's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Disc Medicine COGS-to-Revenue Chart

Disc Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
- - - -

Disc Medicine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Disc Medicine COGS-to-Revenue Calculation

Disc Medicine's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Disc Medicine's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Disc Medicine  (NAS:IRON) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Disc Medicine's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Disc Medicine COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Disc Medicine's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Disc Medicine (Disc Medicine) Business Description

Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firm's pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism.
Executives
Kevin Bitterman director C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mona Ashiya director, 10 percent owner C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8
William Richard White director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Joanne Bryce officer: Chief Financial Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Rahul Khara officer: General Counsel C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
William Jacob Savage officer: Chief Medical Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Brian Richard Macdonald officer: Chief Innovation Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Ai Dmi Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Atlas Venture Associates Opportunity I, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, Llc 10 percent owner 400 TECH. SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019

Disc Medicine (Disc Medicine) Headlines

From GuruFocus